INTRA-CELLULAR THERAPIES INC. - COMMON STOCK

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

07 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Prices Public Offering of Common Stock

04 Jan 2022 21:08:26 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

03 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

20 Dec 2021 05:47:22 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

06 Dec 2021 15:01:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

09 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

02 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20

18 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs

08 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

27 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

22 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging

20 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

10 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

09 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

02 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

07 Jun 2021 07:00:02 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

26 May 2021 07:00:02 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

10 May 2021 06:30:00 By Nasdaq GlobeNewswire